Edition:
United States

OBI Pharma Inc (4174.TWO)

4174.TWO on Gre Tai Securities Market of Chinese Taipei

306.00TWD
24 Mar 2017
Change (% chg)

NT$3.00 (+0.99%)
Prev Close
NT$303.00
Open
NT$306.00
Day's High
NT$307.00
Day's Low
NT$302.00
Volume
874
Avg. Vol
1,662,593
52-wk High
NT$630.00
52-wk Low
NT$226.00

Latest Key Developments (Source: Significant Developments)

OBI Pharma says no dividend for 2016
Friday, 10 Mar 2017 02:41am EST 

OBI Pharma Inc <4174.TWO>:Says no dividend for 2016.  Full Article

OBI Pharma signs letter of intent to acquire 70 pct stake in AP Biosciences via new share issuance
Friday, 30 Dec 2016 04:15am EST 

OBI Pharma <4174.TWO>:Says it signed a letter of intent with AbProtix, Inc. to acquire 70 percent stake in AP Biosciences via new share issuance.  Full Article

OBI Pharma Inc - Wong Chi-Huey withdraws resignation amid insider trading probe - Nikkei - Reuters News
Monday, 18 Apr 2016 09:13am EDT 

OBI Pharma Inc:Taiwan's Academia Sinica President Wong Chi-Huey withdrew resignation, pledged to answer queries on insider trading probe related to Obi Pharma - Nikkei.  Full Article

OBI Pharma says no dividend payment for 2015
Friday, 25 Mar 2016 04:46am EDT 

OBI Pharma, Inc:Says no dividend payment to shareholders for 2015.  Full Article

OBI Pharma says OBI-822 has ability to produce antibodies
Sunday, 21 Feb 2016 02:33am EST 

OBI Pharma, Inc:Says OBI-822, which is a breast cancer therapeutic vaccine, has ability to produce antibodies, according to the clinical trial.  Full Article

OBI Pharma, Inc. enters exclusive agreement with MSD for rights to DIFICID (fidaxomicin) in Taiwan
Sunday, 4 Oct 2015 05:58am EDT 

OBI Pharma, Inc:Says an agreement with MSD, known as Merck in the United States and Canada, through a subsidiary transferring exclusive rights to develop and commercialize Dificid (fidaxomicin) in Taiwan to MSD.Says this agreement will enable the launch of Dificid in Taiwan utilizing MSD's extensive market expertise and knowledge, with the potential to benefit patients in Taiwan suffering from Clostridium Difficile- Associated Diarrhea (CDAD).Under the terms of the agreement, OBI Pharma will receive an initial up-front payment of US$3.0 million from MSD and is eligible to receive royalties and payments associated with the completion of certain undisclosed milestones.MSD will be responsible for all future costs associated with commercialization, development, and manufacturing of DIFICID in Taiwan.  Full Article

OBI Pharma cancer treatment vaccine passes human clinical trials review
Monday, 20 Jul 2015 03:56am EDT 

OBI Pharma, Inc:Its cancer treatment vaccine OBI-833 passed human clinical trials review of Ministry of Health and Welfare, Taiwan.  Full Article

More From Around the Web